Search Results

Shasqi, Inc. announced that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 14th Annual World ADC Conference in London, United Kingdom on Tuesday March 12th at 11:00am GMT.

Shasqi, Inc. today announced it will present five posters on the company’s novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024.

Shasqi, Inc. a biotech company whose mission is to make cancer drugs more effective with click chemistry, announced the expansion of its board with the appointment of Pamela M. Klein, M.D., and Mark McCamish M.D., Ph.D.

Shasqi, Inc. (“Shasqi”) a clinical stage biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced the expansion of its ongoing research collaboration with Johnson & Johnson Enterprise Innovation Inc.

Shasqi, Inc. (“Shasqi”), a clinical-stage biotech company, whose mission is to revolutionize cancer treatment with click chemistry, announced today it has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc.

Shasqi, Inc. announced the formation of its Scientific Advisory Board composed of leaders with decades of experience in oncology drug development and translational research.

Shasqi, Inc. announced the expansion of its Click Activated Protodrugs Against Cancer platform with a pivotal manuscript describing the preclinical development of SQ2201, a novel cancer therapy.

Shasqi announced it has opened the Phase 2 of their Phase 1/2a clinical study to further assess SQ3370 in anthracycline- naïve patients.

Shasqi announced that the company’s scientific advisor, Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry, alongside Morten Meldal, Ph.D., and Nobel Laureate K. Barry Sharpless, Ph.D., for the development of click chemistry and bioorthogonal chemistry.

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, will present interim data from its Phase 1 clinical study of SQ3370 in advance solid tumors, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago, IL, on June 3-7, 2022.